[go: up one dir, main page]

AR049010A1 - Formulaciones farmaceuticas para inhaladores de polvos secos que comprenden un ingrediente activo presente en concentraciones reducidas - Google Patents

Formulaciones farmaceuticas para inhaladores de polvos secos que comprenden un ingrediente activo presente en concentraciones reducidas

Info

Publication number
AR049010A1
AR049010A1 ARP050101060A ARP050101060A AR049010A1 AR 049010 A1 AR049010 A1 AR 049010A1 AR P050101060 A ARP050101060 A AR P050101060A AR P050101060 A ARP050101060 A AR P050101060A AR 049010 A1 AR049010 A1 AR 049010A1
Authority
AR
Argentina
Prior art keywords
active ingredient
dry powder
reduced concentrations
pharmaceutical formulations
ingredient present
Prior art date
Application number
ARP050101060A
Other languages
English (en)
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34962706&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR049010(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of AR049010A1 publication Critical patent/AR049010A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una formulacion que será administrada como un polvo seco para inhalaciones que es adecuada para la administracion eficaz de ingredientes activos presentes en concentraciones reducidas en las vías respiratorias inferiores de pacientes. En particular, provee una formulacion que comprende micropartículas constituidas por partículas de un ingrediente activo presente en concentraciones reducidas y partículas de un excipiente, donde la mediana del diámetro de masa (MMD) de las micropartículas comprende entre 2 y 15 micrones, al menos un 10% de las micropartículas tiene un diámetro de masa (MD) mayor que 0,5 micrones, la relacion entre el ingrediente activo y el excipiente comprende entre 1:5 y 1:00 por ciento en peso. Polvo para su uso en un inhalador de polvo seco y proceso para preparar dicho polvo.
ARP050101060A 2004-03-17 2005-03-18 Formulaciones farmaceuticas para inhaladores de polvos secos que comprenden un ingrediente activo presente en concentraciones reducidas AR049010A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04006430 2004-03-17

Publications (1)

Publication Number Publication Date
AR049010A1 true AR049010A1 (es) 2006-06-21

Family

ID=34962706

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101060A AR049010A1 (es) 2004-03-17 2005-03-18 Formulaciones farmaceuticas para inhaladores de polvos secos que comprenden un ingrediente activo presente en concentraciones reducidas

Country Status (19)

Country Link
US (1) US8153104B2 (es)
EP (1) EP1729728B1 (es)
KR (1) KR20060130216A (es)
CN (1) CN1942172B (es)
AR (1) AR049010A1 (es)
AU (1) AU2005224008B2 (es)
BR (1) BRPI0508170A (es)
CA (1) CA2560226C (es)
ES (1) ES2566618T3 (es)
JO (1) JO3102B1 (es)
MA (1) MA28514B1 (es)
MX (1) MXPA06010593A (es)
NO (1) NO342481B1 (es)
NZ (1) NZ549870A (es)
PE (1) PE20060716A1 (es)
RU (1) RU2371171C2 (es)
TN (1) TNSN06277A1 (es)
WO (1) WO2005089717A1 (es)
ZA (1) ZA200607700B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1944018A1 (en) 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
AU2008217586A1 (en) * 2007-02-19 2008-08-28 Cipla Limited Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
EP2191821A1 (en) 2008-11-26 2010-06-02 CHIESI FARMACEUTICI S.p.A. Microparticles comprising a salt of 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone having improved adhesion properties for dry powder inhalation
TWI491416B (zh) * 2008-12-24 2015-07-11 Daiichi Sankyo Co Ltd 吸入用乾燥粉末醫藥組成物
CA2770714A1 (en) * 2009-08-27 2011-03-17 Stc.Unm Methods and systems for dosing and coating inhalation powders onto carrier particles
EP2360147A1 (en) * 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)
WO2011120779A1 (en) * 2010-04-01 2011-10-06 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
DE102011102614A1 (de) * 2011-05-27 2012-11-29 Roland Nied Verfahren zum Betrieb einer Strahlmühle sowie Strahlmühle
WO2013077830A1 (en) * 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
RS63759B1 (sr) * 2012-01-25 2022-12-30 Chiesi Farm Spa Formulacija suvog praha koja sadrži kortikosteroid i beta-adrenergik, za primenu inhalacijom
CN107875127A (zh) * 2012-02-28 2018-04-06 艾塞尤提卡控股公司 可吸入药物组合物
CN104470503A (zh) 2012-04-13 2015-03-25 葛兰素史克知识产权开发有限公司 聚集粒子
JP5087182B1 (ja) * 2012-06-13 2012-11-28 クリニプロ株式会社 吸入用パウダーの製造方法
US10441536B2 (en) * 2013-03-13 2019-10-15 Actavis Group Ptc Ehf Micronized colistimethane sodium pharmaceutical compositions
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
CA2917752C (en) * 2013-07-11 2022-05-03 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
CN104800192A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入粉雾剂及制备方法
MA50680A (fr) 2014-09-09 2020-08-05 Vectura Ltd Formulation comprenant glycopyrrolate, procédé et appareil
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
CN109200034A (zh) * 2017-06-30 2019-01-15 正大天晴药业集团股份有限公司 一种可吸入干粉形式的组合物及其制备方法
GB201911517D0 (en) * 2019-08-12 2019-09-25 Verona Pharma Plc Pharmaceutical composition
KR20220114042A (ko) * 2019-12-16 2022-08-17 씨젠 인크. 부형제의 고성능 액체 크로마토그래피 정량 방법
WO2021236570A1 (en) * 2020-05-18 2021-11-25 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing remdesivir and its active metabolites for dry powder inhalation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE94801T1 (de) * 1990-01-29 1993-10-15 Ciba Geigy Ag Verfahren und vorrichtung zur dosierung eines feinkoernigen pulvers.
US6673335B1 (en) * 1992-07-08 2004-01-06 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized medicaments
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
US20010006939A1 (en) * 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
GB9925934D0 (en) * 1999-11-03 1999-12-29 Glaxo Group Ltd Novel apparatus and process
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
KR20030038690A (ko) * 2000-08-07 2003-05-16 인헤일 테라퓨틱 시스템즈 인크. 응집이 최소화된, 흡입성 분무 건조 4-나선 다발 단백질분말
US6587025B2 (en) * 2001-01-31 2003-07-01 Vishay Dale Electronics, Inc. Side-by-side coil inductor
EP1643974A1 (en) * 2003-07-11 2006-04-12 Glaxo Group Limited Inhalable pharmaceutical formulations comprising a sugar ester
EP2080508A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug

Also Published As

Publication number Publication date
PE20060716A1 (es) 2006-07-25
EP1729728B1 (en) 2016-03-16
RU2371171C2 (ru) 2009-10-27
KR20060130216A (ko) 2006-12-18
AU2005224008A1 (en) 2005-09-29
MA28514B1 (fr) 2007-04-03
US20070202053A1 (en) 2007-08-30
NO20064161L (no) 2006-10-17
HK1101346A1 (en) 2007-10-18
MXPA06010593A (es) 2007-02-16
CA2560226A1 (en) 2005-09-29
BRPI0508170A (pt) 2007-08-07
CN1942172A (zh) 2007-04-04
CA2560226C (en) 2013-07-23
NZ549870A (en) 2010-05-28
TNSN06277A1 (en) 2007-12-03
RU2006133038A (ru) 2008-03-20
WO2005089717A1 (en) 2005-09-29
ES2566618T3 (es) 2016-04-14
AU2005224008B2 (en) 2010-09-16
CN1942172B (zh) 2010-10-06
EP1729728A1 (en) 2006-12-13
JO3102B1 (ar) 2017-09-20
NO342481B1 (no) 2018-05-28
US8153104B2 (en) 2012-04-10
ZA200607700B (en) 2008-05-28

Similar Documents

Publication Publication Date Title
AR049010A1 (es) Formulaciones farmaceuticas para inhaladores de polvos secos que comprenden un ingrediente activo presente en concentraciones reducidas
NO20024973D0 (no) Farmasöytiske formuleringer for törr pulver inhalatorer
US20230075885A1 (en) Compositions and applications thereof
WO2021236570A1 (en) Pharmaceutical formulation containing remdesivir and its active metabolites for dry powder inhalation
WO2021212183A1 (en) Products of manufacture and methods for treating, ameliorating or preventing microbial infections
CA2483917C (en) Formulations limiting spread of pulmonary infections
US20220241307A1 (en) Inhaled ivermectin
CN112791097A (zh) 碘在制备预防、治疗呼吸道感染性疾病的药物中的应用以及制备低粒径含碘气溶胶的方法
EP2627336A1 (en) Method for treating cystic fibrosis with inhaled denufosol
KR20230005937A (ko) 바이러스 감염의 치료 또는 예방을 위한 클로파지민 조성물 및 방법
Balducci et al. Drug delivery strategies for pulmonary administration of antibiotics
CN116437903A (zh) 肝素组合物在通过吸入途径通过软雾吸入器或振动网状技术雾化器治疗病毒性肺病、急性和/或慢性肺病中的用途
Bhutkar et al. Novel Drug Delivery Systems in the Management of Asthma and Pulmonary Diseases
US20240074971A1 (en) Nano- ivermectin compositions
TH75699A (th) สูตรผสมทางเภสัชกรรมสำหรับเครื่องพ่นยาผงแห้ง ซึ่งประกอบรวมด้วยส่วนประกอบออกฤทธิ์ที่มีความแรงของขนาดยาต่ำ

Legal Events

Date Code Title Description
FA Abandonment or withdrawal